JP2007511516A5 - - Google Patents

Download PDF

Info

Publication number
JP2007511516A5
JP2007511516A5 JP2006539843A JP2006539843A JP2007511516A5 JP 2007511516 A5 JP2007511516 A5 JP 2007511516A5 JP 2006539843 A JP2006539843 A JP 2006539843A JP 2006539843 A JP2006539843 A JP 2006539843A JP 2007511516 A5 JP2007511516 A5 JP 2007511516A5
Authority
JP
Japan
Prior art keywords
beneficial agent
administration
anesthetics
anesthetic
gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006539843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007511516A (ja
Filing date
Publication date
Priority claimed from US10/985,116 external-priority patent/US20050281879A1/en
Application filed filed Critical
Publication of JP2007511516A publication Critical patent/JP2007511516A/ja
Publication of JP2007511516A5 publication Critical patent/JP2007511516A5/ja
Pending legal-status Critical Current

Links

JP2006539843A 2003-11-14 2004-11-12 薬品送達ビヒクル中の賦形剤 Pending JP2007511516A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51997203P 2003-11-14 2003-11-14
US10/985,116 US20050281879A1 (en) 2003-11-14 2004-11-10 Excipients in drug delivery vehicles
PCT/US2004/037606 WO2005048989A1 (en) 2003-11-14 2004-11-12 Excipients in drug delivery vehicles

Publications (2)

Publication Number Publication Date
JP2007511516A JP2007511516A (ja) 2007-05-10
JP2007511516A5 true JP2007511516A5 (https=) 2007-07-26

Family

ID=34623114

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006539843A Pending JP2007511516A (ja) 2003-11-14 2004-11-12 薬品送達ビヒクル中の賦形剤

Country Status (14)

Country Link
US (1) US20050281879A1 (https=)
EP (1) EP1691785A4 (https=)
JP (1) JP2007511516A (https=)
KR (1) KR20060125748A (https=)
AR (1) AR046842A1 (https=)
AU (2) AU2004291077A1 (https=)
BR (1) BRPI0416032A (https=)
CA (1) CA2545913C (https=)
IL (1) IL175601A0 (https=)
MX (1) MXPA06005464A (https=)
NO (1) NO20062781L (https=)
PE (1) PE20050494A1 (https=)
TW (1) TW200524631A (https=)
WO (1) WO2005048989A1 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2355385C2 (ru) * 2002-11-06 2009-05-20 Алза Корпорейшн Композиции пролонгированного действия с контролируемым высвобождением
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
DE602006020568D1 (de) * 2005-07-02 2011-04-21 Arecor Ltd Stabile wässrige systeme mit proteinen
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
AU2013202598B2 (en) * 2005-09-30 2016-06-09 Durect Corporation Sustained release small molecule drug formulation
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US7261742B2 (en) 2005-10-13 2007-08-28 S.C. Johnson & Son, Inc. Method of deodorizing a textile
US7407922B2 (en) 2005-10-13 2008-08-05 S.C. Johnson & Son, Inc. Deodorizing compositions
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
EP2167039B1 (en) 2007-05-18 2016-09-28 Durect Corporation Improved depot formulations
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
WO2009110939A2 (en) * 2007-12-10 2009-09-11 Massachusetts Institute Of Technology Drug delivery system for pharmaceuticals and radiation
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US8956642B2 (en) * 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US20100016808A1 (en) * 2008-07-17 2010-01-21 Bioform Medical, Inc. Thin-Walled Delivery System
ES2344674B1 (es) * 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2013142996A1 (en) * 2012-03-30 2013-10-03 The Royal Institution For The Advancement Of Learning/Mcgill University Magnesium phosphate gels
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
EA033537B1 (ru) 2013-03-11 2019-10-31 Durect Corp Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA3015557C (en) 2014-11-07 2019-07-16 Indivior Uk Limited The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
US11090296B2 (en) * 2015-03-18 2021-08-17 Santen Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition
RU2730996C2 (ru) 2015-06-03 2020-08-26 Интарсия Терапьютикс, Инк. Системы установки и извлечения имплантата
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
CN107708738B (zh) * 2015-07-01 2022-03-25 参天制药株式会社 含有柠檬酸酯的贮库制剂
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN105295310A (zh) * 2015-11-11 2016-02-03 苏州国泰科技发展有限公司 一种绿色环保型增塑剂
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US630200A (en) * 1899-03-13 1899-08-01 Draper Co Warp-stop-motion mechanism.
US4443340A (en) * 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
US4985404A (en) * 1984-10-04 1991-01-15 Monsanto Company Prolonged release of biologically active polypeptides
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
DE69311538D1 (de) * 1992-03-12 1997-07-17 Alkermes Inc Acth enthaltende mikrokugeln mit gesteuerter abgabe
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
CA2150803C (en) * 1992-12-02 2006-01-31 Henry Auer Controlled release growth hormone containing microspheres
JP4259610B2 (ja) * 1994-04-08 2009-04-30 キューエルティー・ユーエスエイ・インコーポレーテッド 液体デリバリー組成物
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US6184227B1 (en) * 1995-07-21 2001-02-06 Savvipharm Inc. Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
US5801012A (en) * 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
JP4642946B2 (ja) * 1996-12-20 2011-03-02 アルザ コーポレイション ゲル組成物および方法
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
JP3077635B2 (ja) * 1997-06-20 2000-08-14 日本電気株式会社 高速無線アクセス装置
JP2002532210A (ja) * 1998-12-18 2002-10-02 アンジオソニックス インコーポレイテッド 超音波により癌および他の細胞増殖性疾病を阻止および治療する方法
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
CA2446060A1 (en) * 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
JP5170935B2 (ja) * 2001-11-14 2013-03-27 デュレクト コーポレーション 注入可能なデポー組成物
EP1446101B1 (en) * 2001-11-14 2011-03-23 Durect Corporation Catheter injectable depot compositions and uses thereof
DE60239952D1 (de) * 2001-11-14 2011-06-16 Durect Corp Injizierbare depotzusammensetzungen und deren verwendung
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles

Similar Documents

Publication Publication Date Title
JP2007511516A5 (https=)
US10765677B2 (en) Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
JP4922762B2 (ja) 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
JP4619894B2 (ja) 粘膜表面への、薬剤化合物の送達に適する薬剤キャリアデバイス
JP5786195B2 (ja) 舌下フィルム
IL174562A0 (en) Oros push-stick for controlled delivery of active agent
JP2006522149A5 (https=)
JP2010533225A5 (https=)
CA2531833A1 (en) Poly-4-hydroxybutyrate matrices for sustained drug delivery
DK1740154T3 (da) Insulinsammensætninger med forbedret absorption
ES2530719T3 (es) Formulaciones de oxicodona para ser administradas una vez al día
CA2628200A1 (en) Solid pharmaceutical compositions containing pregabalin
US20210308040A1 (en) Ketamine oral transmucosal delivery system
ATE432689T1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
CA2601304A1 (en) Controlled release formulations of octreotide
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
JP2006512324A5 (https=)
JP2005002009A (ja) フェンタニル含有口腔粘膜貼付剤
JP2006514967A5 (https=)
BR0315316A (pt) Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
JP2008534503A5 (https=)
JP2005521662A (ja) プロトンポンプ阻害剤の経粘膜送達
BRPI0519022A2 (pt) formaÇço insitu de implante para animais
JP2002226315A (ja) 義歯用口腔湿潤剤
JP6959313B2 (ja) 口腔内貼付剤